Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Rated “Buy” by Sell-Side Brokerages

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has received an average recommendation of “Buy” from the eleven research firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $27.14.

A number of research analysts have recently commented on ZVRA shares. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research report on Thursday, August 6th. BTIG Research dropped their target price on Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a research report on Monday, July 27th. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Finally, HC Wainwright reissued a “buy” rating and issued a $26.00 target price on shares of Zevra Therapeutics in a research report on Thursday, August 20th.

Key Zevra Therapeutics News

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: HC Wainwright increased its EPS estimates for Q4 2026 to $0.14 from $0.13, FY2026 to $0.91 from $0.68, and FY2027 to $0.66 from $0.55. It also lifted estimates for FY2028–FY2030 and retained a Buy rating with a $26 target. The upward revisions point to improved analyst expectations for future earnings.
• Positive Sentiment: Cantor Fitzgerald kept its Buy rating on Zevra Therapeutics, reinforcing the positive analyst outlook. Cantor Fitzgerald Keeps Their Buy Rating on Zevra Therapeutics
• Positive Sentiment: BTIG also gave Zevra a Buy rating, adding to the favorable analyst sentiment. Zevra Therapeutics Receives a Buy from BTIG

Zevra Therapeutics Price Performance

Shares of NASDAQ:ZVRA opened at $11.59 on Monday. The firm has a market capitalization of $689.66 million, a PE ratio of 9.74 and a beta of 1.01. The business has a 50-day moving average of $11.07 and a two-hundred day moving average of $10.78. Zevra Therapeutics has a 12 month low of $8.01 and a 12 month high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.10. The company had revenue of $37.76 million during the quarter, compared to analyst estimates of $37.08 million. Zevra Therapeutics had a net margin of 52.80% and a return on equity of 54.64%. As a group, research analysts anticipate that Zevra Therapeutics will post 0.88 earnings per share for the current year.

Insider Buying and Selling at Zevra Therapeutics

In related news, CEO Neil McFarlane sold 20,000 shares of the business’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $11.25, for a total transaction of $225,000.00. Following the completion of the sale, the chief executive officer owned 417,225 shares of the company’s stock, valued at $4,693,781.25. This represents a 4.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.70% of the company’s stock.

Institutional Trading of Zevra Therapeutics

Large investors have recently added to or reduced their stakes in the business. AIGH Capital Management LLC bought a new position in Zevra Therapeutics during the 1st quarter valued at $11,184,000. Bank of New York Mellon Corp bought a new position in shares of Zevra Therapeutics during the 2nd quarter valued at about $2,846,000. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Zevra Therapeutics by 116.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock worth $5,502,000 after purchasing an additional 206,543 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Zevra Therapeutics by 259.2% during the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after buying an additional 400,336 shares in the last quarter. Finally, Integrity Alliance LLC. bought a new position in shares of Zevra Therapeutics in the third quarter valued at $10,292,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.